PeopleImages/iStock via Getty Images Investment Thesis In this article, I will analyze the field of biopharma through two industry competitors: AbbVie (NYSE:ABBV, NEOE:ABBV:CA) and GSK (NYSE:GSK, OTCPK:GLAXF). I aim to illustrate the levels of their operation, which will specifically highlight AbbVie's pursuit to create medical breakthroughs and GSK's strategic abilities in the industry (and much more). We will discuss some valuation metrics to find if there is deep value in either security, too. Their ...

Maksymenko Nataliia Created by the author The S&P 500 Dividend Aristocrats Index contains 67 dividend growth [DG] stocks called the Dividend Aristocrats. With a few exceptions, the Dividend Aristocrats are S&P 500 companies with higher dividend payouts every year for 25 or more years. Based on their quality scores, I rate stocks as Exceptional (29-30), Excellent (26-28), Fine (21-25), Decent (16-20), Poor (11-15), and Inferior (0-10). Investment Grade ratings have quality scores in the range of 16-30, while ...

Drugmaker AbbVie (ABBV 0.38%) spun off from Abbott Laboratories (ABT 1.03%) at the start of 2013. The growth-oriented pharma business has become a beast, generating more than $58 billion in revenue last year -- far more than Abbott's top line, which totaled just under $44 billion.But today, AbbVie faces some challenges as its top-selling drug Humira is losing patent protection and its sales have been declining sharply. Abbott, meanwhile, isn't just some stale business. Its diabetes products have been genera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction o ...

AbbVie Inc. (NYSE:ABBV) Q3 2023 Earnings Conference Call October 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer Scott Reents - Executiv ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_2922146a73ee5d3b7f807719ee8b54cc.html ...

PRESS RELEASE AbbVie Reports Second-Quarter 2023 Financial Results • Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis • Second-Quarter Global Net Revenues ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35565 AbbVie Inc. (Exact name of registrant as specified in its charter) Delaware 32-0375147 (State or other jurisdiction of inc ...

AbbVie Inc. (NYSE:ABBV) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President & Chief Operating Officer Jeff Stewart - Executive Vice President & Chief Commercial Officer Carrie Strom - Senior Vice President, AbbVie and President, Global Allergan Aesthetics Tom Hudson - Senior Vice President, R&D & Chief Scientific Officer Scott Reents - Executive V ...

AbbVie Inc. (NYSE:ABBV) Goldman Sachs 44th Annual Global Healthcare Conference Call June 14, 2023 11:00 AM ET Company Participants Rob Michael - President and Vice Chair Jeff Stewart - Chief Commercial Officer Roopal Thakkar - Chief Medical Officer Conference Call Participants Chris Shibutani - Goldman Sachs Chris Shibutani Okay. Here we go. Good morning, everybody and welcome to Wednesday, third day of the 44th Annual Goldman Sachs Healthcare Conference. Congratulations to all of you who have survived, hop ...